1734PD - Anti-CTGF human recombinant monoclonal antibody pamrevlumab increases resectability and resection rate when combined with gemcitabine/Nab-paclitaxel in the treatment of locally advanced pancreatic cancer patients

E Carrier,V Picozzi,M.J Pishvaian,K Mody,J Winter,J Glaspy,T Larson,W.C Conway,K Lipson,S Porter,E Kouchakji

doi:10.1093/annonc/mdx369.166

1734PD - Anti-CTGF human recombinant monoclonal antibody pamrevlumab increases resectability and resection rate when combined with gemcitabine/Nab-paclitaxel in the treatment of locally advanced pancreatic cancer patients

E Carrier, V Picozzi + Show 9 more

Open Access

https://doi.org/10.1093/annonc/mdx369.166

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2017
Citations: 3	License type: publisher-specific-oa

Affiliation: FibroGen (United States), Virginia Mason Medical Center, Georgetown University, Mayo Clinic, Winneshiek Medical Center, Thomas Jefferson University, Ronald Reagan UCLA Medical Center, Minnesota Oncology

#Resectability Rate #Anti-CTGF Antibody + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1734PD - Anti-CTGF human recombinant monoclonal antibody pamrevlumab increases resectability and resection rate when combined with gemcitabine/Nab-paclitaxel in the treatment of locally advanced pancreatic cancer patients

Full Text